Cardiac adverse events after Chimeric Antigen Receptor (CAR) T cell therapies: an updated systematic review and meta-analysis-Reference-Cited by-同舟云学术

Cardiac adverse events after Chimeric Antigen Receptor (CAR) T cell therapies: an updated systematic review and meta-analysis

Published:2024-08-20 Issue:1 Volume:10 Page:
ISSN:2057-3804
Container-title:Cardio-Oncology
language:en
Short-container-title:Cardio-Oncology

Author:

Maleki Saba,Esmaeili Zahra,Seighali Niloofar,Shafiee Arman,Namin Sara Montazeri,Zavareh Mohammad Amin Tofighi,Khamene Sima Shamshiri,Mohammadkhawajah Izat,Nanna Michael,Alizadeh-asl Azin,M.Kwan Jennifer,Hosseini Kaveh

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s40959-024-00252-y.pdf

Reference51 articles.

1. Stein-Merlob AF, Rothberg MV, Holman P, Yang EH. Immunotherapy-associated cardiotoxicity of immune checkpoint inhibitors and chimeric antigen receptor T cell therapy: diagnostic and management challenges and strategies. Curr Cardiol Rep. 2021;23(3):11.

2. Burns EA, Gentille C, Trachtenberg B, Pingali SR, Anand K. Cardiotoxicity associated with anti-CD19 chimeric antigen receptor T-cell (CAR-T) Therapy: recognition, risk factors, and management. Diseases. 2021;9(1):20.

3. Camilli M, Maggio L, Tinti L, Lamendola P, Lanza GA, Crea F, et al. Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: a clinical appraisal. Front Cardiovasc Med. 2023;10:1090103.

4. Patel NP, Doukas PG, Gordon LI, Akhter N. Cardiovascular toxicities of CAR T-cell therapy. Curr Oncol Rep. 2021;23(7):78.

5. Marar RI, Abbasi MA, Prathivadhi-Bhayankaram S, Daryanani A, Villarraga H, Anavekar N, et al. Cardiotoxicities of novel therapies in hematologic malignancies: chimeric antigen receptor T-cell therapy and bispecific t-cell engager therapy. JCO Oncol Pract. 2023;19(6):331–42.